Non-Insulin Therapies for Diabetes Market Key Trends, End User, Types, Applications, Countries & Forecast to 2022-2030
Non-Insulin Therapies for Diabetes Market: Introduction
Patients with type 2 diabetes who either don't convey enough insulin or can't adequately use the insulin they make typically receive non-insulin therapy. Non-insulin-based medications lower blood glucose levels and maintain optimum glycemic control by combining various activities.
For instance, certain administrators (Sulfonylureas) stimulate the release of insulin from pancreatic cells, whereas other professionals boost peripheral glucose uptake and decrease hepatic glucose yield (Biguanides), On the other hand, many medications (alpha glucosidase inhibitors) stop the small intestine from absorbing starch, and some treatments reduce post-meal sugar by obstructing a particular molecule.
Global Non-Insulin Therapies for Diabetes Market Forecast:
The Global Non-Insulin Diabetes Therapies Market size was at US$ 16.26 Billion in 2021, and it is predicted that it will reach a valuation of US$ 26.55 Billion by the end of 2030 with an annual development rate (CAGR) of 5.6% between 2022 and 2030.
Global Non-Insulin Therapies for Diabetes Market Overview:
Rise in the number of people affected by Diabetes Type 2 is the key factor aiding market growth. The number of affected people is expected to increase to 642 million by 2040. Furthermore, the progression of the market is also credited to the engagement of companies in developing medicines with lesser side effects. Non-insulin drugs are injected into the body, to help liver in producing insulin. Previously, insulin type drugs ruled the market, but it is expected that very soon, the market will be dominated by Non-Insulin drugs. The market is anticipated to grow rapidly, and this expansion is ascribed to the rise in the number of diabetes patients, which is caused due to the change in lifestyle and food habits.
Producing a drug which has lesser side effect and is more effective than the currently used drugs are the primary challenges for this market. People are still not aware of the benefits of these drugs. Since diabetes is a common disease, it has been difficult to make this drug available to people from all classes. Another big challenge is to make people aware of the functioning and uses of drugs. The key market players of this segment are located in a few regions only; hence market penetration of the drug is not so deep, which has resulted in less awareness and low sales. Furthermore, the market is also being restricted due to insignificant government initiatives towardsincreasing the cognizance of the masses.
Non-Insulin Therapies for Diabetes Market: Key trends
Developing Prevalence of Non-Invasive Treatments to Dive the Growth
Growing overall rate and preponderance of diabetes is depended upon to fuel advancement of the non-insulin treatment for diabetes promote. Non-insulin treatment is prevalently used in type 2 diabetes, which addresses a huge share of the overall diabetes cases. As demonstrated by the International Diabetes Federation's (IDF) Diabetes Atlas 2017, generally frequency of diabetic patients was more than 400 million, of which larger part were encountering type 2 diabetes. As per the World Health Organization (WHO) 2017 report, diabetes is one of the super three reasons behind death among non-infectious diseases globally. This is the main consideration that supports the expansion of worldwide non-insulin therapies for diabetes market.
Request a sample copy of This Market: https://wemarketresearch.com/sample-request/non-insulin-therapies-for-diabetes-market/39/
New Product Launches to Boost the Growth
Healthcare companies and related organizations are launching and approving new products and treatments in the market, which is depended upon to drive increment of the overall non-insulin treatment for diabetes market. For instance, in 2017, the Food and Drug Administration (FDA) avowed Novo Nordisk's Ozempic, which is before seven days GLP-1 simple, would assemble the patient consistence. In December 2017, FDA insisted ertugliflozin made by the Merck and Co. additionally, Pfizer Inc. similarly, in January 2018, the European Medicines Agency (EMA) permitted support for the equivalent in Europe.
Key Market Segmentation of the Global Non-Insulin Therapies for Diabetes Market:
Global Non-Insulin Therapies for Diabetes Market can be divided into Drug Types, Route of Administration, Distribution Channel, and Geographical landscapes, etc.
- Boehringer Ingelheim GmbH,
- Bristol-Myers Squibb,
- Eli Lilly and Company,
- Hoffmann-La Roche Ltd.,
- Janssen Pharmaceuticals,
- Merck and Company,
- Novartis AG,
- Novo Nordisk,
- Sanofi Aventis,
- INTARCIA THERAPEUTICS
- JIANGSU HANSOH PHARMACEUTICAL
- NOVO NORDISK
- UNI-BIO SCIENCE GROUP
- Takeda Pharmaceuticals
Non-Insulin Therapies for Diabetes Market Segmentation By Drug Type:
- Amylin Agonists
- GLP-1 Agonists & Analogs
- Glinides & Meglinitides
- Sodium-Glucose cotransporter 2 (SGLT2) Inhibitors
- Thiazolidinediones (or Glitazones or TZDs
- Alpha-Glucosidase Inhibitors
- Dipeptidyl Peptidase-4 (DPP4) Inhibitors
Non-Insulin Therapies for Diabetes Market Segmentation By Route of Administration:
Non-Insulin Therapies for Diabetes Market Segmentation By Distribution Channel:
- Retail Pharmacy
- Hospital Pharmacy
- Online Pharmacy
Non-Insulin Therapies for Diabetes Market Segmentation By Geographical Landscape:
- North America
- Asia Pacific
- South America
- Middle East and Africa
Major Key Players in the Global Non-Insulin Therapies for Diabetes Market Are:
- Tobira (New Jersey),
- Eli Lilly and Sumitomo Dainippon Pharma (Japan),
- Novo Nordisk A/S (Denmark),
- The Takeda Pharmaceutical Company (Japan),
- Sanofi SA (China),
- Mannkind Corporation (California),
- Bristol-Myers Squibb (New York),
- AstraZeneca plc (U.K),
- Boehringer Ingelheim (Germany)
- Bayer AG (Germany).
The Covid-19 Impact Analysis:
The COVID-19 pandemic brought about a major global crisis and the rising number of new positive cases were a cause for concern for the whole world. The coronavirus and its effects on the body were being studied by scientists and pharmaceutical companies worldwide. The coronavirus had severely affected many people having heart ailments, diabetes and other co-morbidities.
Therefore, the non-insulin drug market witnessed significant growth during the pandemic. People needed to treat their diabetes so that coronavirus did not become a deadly catalyst that harshly affected the body. The lockdown stopped the supply and demand chain from being at the same level, and therefore the gap created between supply and demand was still needed to be filled. Due to indefinite lockdowns, diabetic patients could not see their doctor as the people's movement was prohibited; therefore, it hampered the progression of the Non-Insulin Therapies market.
Purchase This Market Research Report:- https://wemarketresearch.com/purchase/non-insulin-therapies-for-diabetes-market/39/?license=single
Key questions answered in this report:
- What is the market size and growth rate forecast for Non-Insulin Therapies for Diabetes?
- What are the main driving factors propelling the Non-Insulin Therapies for Diabetes Market forward?
- What are the leading companies in the Non-Insulin Therapies for Diabetes Industry?
- What segments do the Non-Insulin Therapies for Diabetes Market cover?
- How can I receive a free copy of the Non-Insulin Therapies for Diabetes Market sample report and company profiles?
About We Market Research
WE MARKET RESEARCH is an established market analytics and research firm with a domain experience sprawling across different industries. We have been working on multi-county market studies right from our inception. Over the time, from our existence, we have gained laurels for our deep rooted market studies and insightful analysis of different markets.
Our strategic market analysis and capability to comprehend deep cultural, conceptual and social aspects of various tangled markets has helped us make a mark for ourselves in the industry. WE MARKET RESEARCH is a frontrunner in helping numerous companies; both regional and international to successfully achieve their business goals based on our in-depth market analysis. Moreover, we are also capable of devising market strategies that ensure guaranteed customer bases for our clients.